RecruitingPhase 4NCT06486792

Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

1,148 participants

Start Date

Jun 18, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay. After discharge, these patients are typically monitored for AF using devices like Holter monitors or implantable loop recorders. Treatment options during this period include anticoagulants or aspirin. Anticoagulants are more effective in preventing recurrent strokes if AF is present, offering an 80% risk reduction compared to aspirin's 20%. If AF is detected, anticoagulant treatment continues; if not, patients may switch to aspirin after 6-12 months. Despite the clinical rationale for using anticoagulants during this search period, their benefit-risk ratio compared to aspirin has not been fully evaluated.


Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Apixaban and a drug called Aspirin for people with atrial fibrillation, cerebral infarction, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 65 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGApixaban

Patients who have had an ischemic stroke will receive either an anticoagulant or aspirin according to their randomization arm.

DRUGAspirin

Aspirin is used as the standard of care


Locations(1)

Bichat Hospital

Paris, Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06486792


Related Trials